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Background
Clinical decision support (CDS) systems have been proved to enhance evidencebased clinical practice and support healthcare cost-effectiveness [1] [2] [3] [4] [5] [6] . According to the definition developed by Edward Shortliffe, there are three levels of CDS functions, these include; 1) managing health information through providing tools for search and retrieval, 2) focusing users' attention through flagging abnormal values or possible drug-to-drug interactions, and 3) providing patient specific recommendations based on the clinical scenario, which usually follow rules and algorithms, cost-benefit analysis or clinical pathways [7, 8] . Clinical predictive tools, here referred to simply as predictive tools, belong to the third level of CDS and include various applications; ranging from the simplest manual clinical prediction rules to the most sophisticated machine learning algorithms [9, 10] . These research-based applications provide diagnostic, prognostic, or therapeutic decision support. They quantify the contributions of relevant patient characteristics to derive the likelihood of diseases, predict their courses and possible outcomes, or support the decision making on their management [11, 12] .
When selecting predictive tools, for implementation in their clinical practice or for recommendation in clinical practice guidelines, clinicians involved in the decision making are challenged with an overwhelming and ever-growing number of tools. Many of these tools have never been implemented or assessed for comparative performance or impact [13] [14] [15] . Currently, clinicians rely on their previous experience, subjective evaluation or recent exposure to predictive tools in making selection decisions.
Objective methods and evidence based approached are rarely used in such decisions [16, 17] . Some clinicians, especially those developing clinical guidelines, search the literature for best available published evidence. Commonly they look for research studies that describe the development, implementation or evaluation of predictive tools. More specifically, some clinicians look for systematic reviews on predictive tools, comparing their predictive performance or development methods. However, there are no available approaches to objectively summarise or interpret such evidence [18, 19] .
The GRASP Framework
To overcome this major challenge, the authors have developed a new evidencebased framework for grading and assessment of predictive tools (The GRASP Framework) [20] . The aim of this framework is to provide clinicians with standardised objective information on predictive tools to support their search for and selection of effective tools for their tasks. Based on the critical appraisal of the published evidence on predictive tools, the GRASP framework uses three dimensions to grade predictive tools: 1) Phase of Evaluation, 2) Level of Evidence and 3) Direction of Evidence.
Phase of Evaluation:
Assigns A, B, or C based on the highest phase of evaluation.
If a tool's predictive performance, as reported in the literature, has been tested for validity, it is assigned phase C. If a tool's usability and/or potential effect have been tested, it is assigned phase B. Finally, if a tool has been implemented in clinical practice, and there is published evidence evaluating its impact, it is assigned phase A.
Level of Evidence:
A numerical score, within each phase, is assigned based on the level of evidence associated with each tool. A tool is assigned grade C1 if it has been tested for external validity multiple times; C2 if it has been tested for external validity only once; and C3 if it has been tested only for internal validity. C0 means that the tool did not show sufficient internal validity to be used in clinical practice. Similarly, B1 is assigned to a predictive tool that has been evaluated during implementation for its usability; while if it has been studied for its potential effect on clinical effectiveness, patient safety or healthcare efficiency, it is assigned B2. Finally, if a predictive tool had been implemented then evaluated after implementation for its impact, on clinical effectiveness, patient safety or healthcare efficiency, it is assigned score A1 if there is at least one experimental study of good quality evaluating its impact, A2 if there are observational studies evaluating its impact and A3 if the impact has been evaluated through subjective studies, such as expert panel reports.
Direction of Evidence:
For each phase and level of evidence, a direction of evidence is assigned based on the collective conclusions reported in the studies. The evidence is considered positive if all studies about a predictive tool reported positive conclusions and negative if all studies reported negative or equivocal conclusions. The evidence is considered mixed if some studies reported positive and some reported either negative or equivocal conclusions. To decide an overall direction of evidence, a protocol is used to sort the mixed evidence into supporting an overall positive conclusion or supporting an overall negative conclusion. The protocol is based on two main criteria; 1) The degree of matching between the evaluation study conditions and the original predictive tool specifications, and 2) The quality of the evaluation study.
Studies evaluating predictive tools in closely matching conditions to the tool specifications and providing high quality evidence are considered first for their conclusions in deciding the overall direction of evidence. The mixed evidence protocol is detailed and illustrated in Figure 6 in the Appendix.
The final grade assigned to a tool is based on the highest phase of evaluation, supported by the highest level of positive evidence, or mixed evidence that supports a positive conclusion. The GRASP framework concept is shown in Figure 1 and the GRASP framework detailed report is presented in Table 3 in the Appendix.
The predictive tool has been tested for internal validity 
Study Objectives
Validating new clinical instruments, healthcare models and evaluation frameworks through the feedback of experts is a well-established approach, especially in the area of CDS [12, 21, 22] . Using a mixed approach of qualitative and quantitative methods in research proved to be useful in healthcare, because of the complexity of the studied topics [23] . Using open-ended questions in quantitative surveys adds significant value and depth to both the results and conclusions of studies conducted [24] . The aim of this study is to validate and update the GRASP framework and to evaluate its reliability. The primary objective is to validate and update the criteria used by the GRASP framework, for grading and assessment of predictive tools, through the feedback of a wide international group of healthcare experts in the areas of developing, implementing and evaluating clinical decision support systems and predictive tools.
The secondary objective is to evaluate the GRASP framework reliability to ensure that the outcomes produced by independent users, when grading predictive tools using the GRASP framework, are accurate, consistent and reliable.
Methods
The Study Design
The study is composed of two parts. The first part includes validating and updating the GRASP framework and the second part includes evaluating the framework reliability. For the first part, a survey was designed to solicit the feedback of experts on the criteria used by the GRASP framework for grading and assessment of predictive tools. The main outcome of this part of the study is to measure the validity and update the design and content of the GRASP framework. The analysis includes evaluating the degree of agreement of experts on how essential the different criteria used to grade predictive tools are, including the three dimensions; phases of evaluation (before, during and after implementation), levels of evidence and directions of evidence within each phase. In addition, experts' feedback on adding, removing or updating any of the criteria, used to grade predictive tools, and their further suggestions and recommendations will also be analysed and considered.
Based on similar studies; validating and updating systems through surveying expert users, it was estimated that the required sample size for this study is around October 2018. The authors expected the distribution of the survey to take two weeks, and the collection of the feedback to take another four weeks. The authors expected the response rate to be around 10%. Before the deployment of the survey a pilot testing was conducted through asking ten experts to take the survey. The feedback of the pilot testing was used to improve the survey design and content; some questions were rephrased, some were rearranged, and some were supported by definitions and clarifications. Experts who participated in the pilot testing were excluded from the participation in the final survey. An invitation email, introducing the study objectives, the survey completion time, which was estimated at 20 minutes, and a participation consent was submitted to the identified experts with the link to the online survey. A reminder email, in two weeks, was sent to the experts who have not responded or completed the survey.
The Study Survey
The online survey was developed using Qualtrics experience management 
Reliability Testing
The second part of this study; evaluating the framework reliability, followed the completion of the first part and used the validated and updated version of the GRASP framework. Two independent and experienced researchers were trained, for four hours each by the authors, on using the framework to grade predictive tools. The researchers were then asked to grade eight different predictive tools independently, using the GRASP framework, the full text studies describing the development of the tools, and the comprehensive list of all the published evidence on each tool along with the full text of each study. The objective of this part of the study was to measure the reliability of using the framework, by independent users, to grade predictive tools. Since the tested function of the GRASP framework here is grading tools, the interrater reliability was the best measure to evaluate its reliability. The interrater reliability, also called interrater agreement, is the degree of agreement or the score of how much homogeneity, or consensus, there is in the ratings given by independent judges [30] . Since the target ratings of the GRASP framework are ordinal, the correlation testing is an appropriate method for showing the interrater reliability. The Spearman's rank correlation coefficient is the best nonparametric correlation estimator. It is widely used in the applied sciences and reported to be a robust measure of correlation [31] . After grading the tools, the two independent researchers were asked to provide their open-ended feedback. Through a short five questions survey, they were asked if the GRASP framework design was logical, if they found it useful, easy to use, their opinion in the criteria used for grading, and if they wish to add, remove, or change any of them.
Analysis and Outcomes
Three major outcomes were planned. Firstly, through the eight closed-ended agreement questions of the survey, the average scores and distributions of experts' opinions on the different criteria used by the GRASP framework to grade and assess the predictive tools should help to improve such criteria. A five-points Likert scale ranging from strongly agree to strongly disagree was used, where the first was assigned the score of five and the last was assigned the score of one, 
Results
The literature search generated a list of 1,186 relevant publications. A total of 882 unique emails were identified and extracted from the publications. In six weeks; from the 4 th of October to the 15 th of November 2018, a total of eighty-one valid responses were received from international experts, with a response rate of 9.2%.
Experts Agreement on GRASP Criteria
The overall average agreement of the eighty-one respondents to the eight closedended questions was 4.35; which means the respondents strongly agreed, overall, to the criteria of the GRASP framework. Respondents strongly agreed to six of the eight closedended agreement questions, regarding the criteria used by the GRASP framework for evaluating predictive tools. They somewhat agreed to one, and were neutral about another one, of the eight closed-ended agreement questions. Table 1 shows the average agreements of the respondents on each of the eight closed-ended questions and Figure   2 shows the averages and distributions of respondents' agreements on each question.
The country distributions of the respondents are shown in Table 6 in the Appendix. Higher than Potential Effect, F -Impact, G -Impact Levels, and H -Evidence Direction
Experts Comments, Suggestions and Recommendations
While the total valid responses were eighty-one; two thirds of the respondents, on average, provided their suggestions or discussed some recommendations for each of the six open-ended free text questions. These questions asked experts for their feedback regarding adding, removing or changing any of the GRASP framework evaluation criteria, their feedback regarding defining and capturing successful tools' predictive performance, when different clinical predictive tasks have different predictive requirements, and their feedback regarding managing conflicting evidence of studies while there is variability in the quality and specifications of published evidence.
Predictive Performance and Performance Levels
The respondents discussed that the method, type, and quality of internal and external validation studies should be reported in the GRASP framework detailed report.
When external validation studies are conducted multiple times using different patient populations, in different healthcare settings, at different institutions, in different countries, over different times, or by different researchers then the tool is said to have a broad validation range, which means it is more reliable to be used across these different variations of healthcare settings. The respondents said that the tool's predictive performance is considered stable and reliable, when multiple external validation studies produce homogeneous predictive performances, e.g. similar sensitivities and specificities. They also discussed adding the concept of "Strength of Evidence"; which should be mainly based on the quality of the reported study and how much the conditions of the study are close to the original specifications of the predictive tool, in terms of clinical area, population, and target outcomes. It should be part of the components of deciding the direction of evidence (positive, negative, or mixed). It should also be reported in the detailed GRASP framework report, so that users can consider when selecting among two or more tools of the same assigned grade. For example, two predictive tools are assigned grade C1 (each was externally validated multiple times) but one of them shows a strong positive evidence and the other shows a medium or weak positive evidence. It is logic to select the tool with the stronger evidence, if both have similar predictive performances for the same tasks.
Usability and Potential Effect
The respondents discussed that the methods and quality of the usability studies and the potential effect studies should be reported in the GRASP framework detailed report. Some of the respondents discussed that the potential effect and usability are not measured during implementation, rather they are measured during the planning for implementation, which is before wide-scale implementation. They also suggested that the details on the potential effect should report the focus on clinical patient outcomes, healthcare outcomes, or provider behaviour. Most of the respondents said that the potential effect is more important than the usability and should have a higher evidence level. A highly usable tool that has no potential effect on healthcare is useless, while a less usable tool that has a promising potential effect is surely better. Some respondents discussed that evaluating both the potential effect and the usability should be considered together as a higher evidence than any of them alone.
Post-Implementation Impact and Impact Levels
The respondents discussed that the method and quality of the postimplementation impact study should be reported in the GRASP framework detailed report. Again, respondents discussed adding the concept of "Strength of Evidence".
Within each evidence level of the post-implementation impact we could have several sub-levels, or at least a classification of the quality of studies. for example, not all observational studies are equal in quality; a case series would be very different to a case control or large-scale prospective cohort study. Within the experimental studies we could also have different sub-levels of evidence, quasi-experimental vs. randomised controlled trial for example. These sub-levels should be included in the GRASP framework detailed report, when reporting the individual studies, this will provide the reader with more details on the strength and quality of the evidence on the tools.
Direction of Evidence
Respondents discussed that the direction of evidence should consider the quality and strength of evidence. Most respondents here used the terms; "quality of evidence"
and "strength of evidence", synonymously. Respondents discussed that quality of evidence or the strength of evidence should consider many elements of the published study, such as the methods used, the appropriate population, appropriate settings, the clinical practice, the sample size, the type of data collection; retrospective vs prospective, the outcomes, the institute of study and any other quality measures. The direction of evidence depends largely on the quality of the evidence, in case there are conflicting conclusions from multiple studies.
Defining and Capturing Predictive Performance
Respondents discussed that the predictive performance evaluation depends basically on the intended prediction task, so this is different from one tool to another, based on the task that each tool does. The clinical condition under prediction and the cost-effectiveness of treatment would highly influence the predictive performance evaluation. Predictive performance evaluation depends also on the actions recommended based on the tool. For example, screening tools should perform with high sensitivity, high negative predictive value, and low likelihood ratio, since there is a following level of checking by clinicians or other tests, while diagnostic tools should always perform with high specificity, high positive predictive value, and high likelihood ratio, since the decisions are based here directly on the outcomes of the tool, and some of these decisions might be risky to the patient or expensive to the healthcare organisation. Respondents discussed that for diagnostic tools, predictive performance is more likely to be expressed through sensitivity and specificity, while for prognostic tools, it is better to express predictive performance through probability/risk estimation.
Predictive tools must always be adjusted to the settings, populations, and the intended tasks before their adoption and implementation in the clinical practice.
Managing Conflicting Evidence
Respondents discussed that deciding on the conflicting evidence should consider the quality of each study or the strength of evidence, to decide on the overall direction of evidence. Measures include the proper methods used in the study, if the population is appropriate, if the settings are appropriate, if the study is conducted at the clinical practice, if the sample size is large, if the data collection was prospective not retrospective, if the outcomes are clearly reported, if the institute of the study is credible, if the study involved multiple sites or hospitals, and any other quality measures related to the methods or the data. We should rely primarily on conclusions from high-quality low risk of bias studies, as recommended in other fields, e.g. systematic reviews. A well designed and conducted study should have more credibility than a poorly designed and conducted study. If different results are obtained for subpopulations, this should be further investigated and explained. The predictive tool may only perform well in certain sub-populations, based on the intended tasks. If we have evidence from settings outside the target population of the tool, then these shouldn't have much weight, or less weight, on the evidence to support the tool, such as nonequivalent studies; which are conducted to validate a tool for a different population, predictive task, or clinical settings. Much of the important information is in the details of the evidence variability. So, it is important to report this in the framework detailed report, to provide as much details as possible for each reported study to help end users make more accurate decisions based on their own settings, intended tasks, target populations, practice priorities, and improvement objectives.
Updating the GRASP Framework
Based on the respondents' feedback, on both the closed-ended evaluation criteria agreement questions and the open-ended suggestions and recommendations questions, the GRASP framework concept was updated, as shown in Figure 3 . Regarding Phase C; the pre-implementation phase including the evidence on predictive performance evaluation, the three levels of internal validation, external validation once, and external validation multiple times, were additionally assigned "Low Evidence", "Medium
Evidence", and "High Evidence" labels respectively. Phase B; During Implementation, has been renamed to "Planning for Implementation". The Potential Effect is now made of higher evidence level than Usability and the evidence of both potential effect and usability together is higher than any one of them alone. Now we have three levels of evidence; B1 = both potential effect and usability are reported, B2 = Potential effect evaluation is reported, and B3 = Usability testing is reported. Figure 4 in the Appendix shows a clean copy of the updated GRASP framework concept.
The GRASP framework detailed report was also updated, as shown in Table 4 in the Appendix. More details were added to the predictive tools information section, such as the internal validation method, dedicated support of research networks, programs, or professional groups, the total citations of the tool, number of studies discussing the tool, the number of authors, sample size used to develop the tool, the name of the journal which published the tool and its impact factor. Table 5 in the Appendix shows the Evidence Summary. This summary table provides users with more information in a structured format on each study discussing the tools, whether these were studies of predictive performance, usability, potential effect or post-implementation impact.
Information includes study name, country, year of development, and phase of evaluation. The evidence summary provides more quality related information, such as the study methods, the population and sample size, settings, practice, data collection method, and study outcomes. Furthermore, the evidence summary provides information on the strength of evidence and a label, to highlight the most prominent or important predictive functions, potential effects or post-implementation impacts of the tools.
We developed a new protocol to decide on the strength of evidence. The strength of evidence protocol considers two main criteria of the published studies. Firstly, it considers the degree of matching between the evaluation study conditions and the original tool specifications, in terms of the predictive task, target outcomes, intended use and users, clinical specialty, healthcare settings, target population, and age group.
Secondly, it considers the quality of the study, in terms of the sample size, data collection, study methods, and credibility of institute and authors. Based on these two criteria, the strength of evidence is classified into 1) strong evidence: matching evidence of high quality, 2) medium evidence: matching evidence of low quality or nonmatching evidence of high quality, and 3) weak evidence: non-matching evidence of low quality. Figure 7 in the Appendix shows the strength of evidence protocol. 
The GRASP Framework Reliability
The two independent researchers assigned grades to the eight predictive tools and produced a detailed report on each one of them. The summary of the two independent researchers assigned grades, compared to the authors, are shown in Table   2 . A more detailed information on the justification of the assigned grades is shown in the Appendix in Table 7 . The Spearman's rank correlation coefficient was 0.994 (p<0.001) comparing the first researcher to the authors, 0.994 (p<0.001) comparing the second researcher to the authors, and 0.988 (p<0.001) comparing the two researchers to each other. This shows a statistically significant and strong correlation, indicating a strong interrater reliability of the GRASP framework. Accordingly, the GRASP framework produced reliable and consistent grades when it was used by independent users. Both independent researchers found GRASP framework design logical, easy to understand, and well organized. They both found GRASP useful, considering the variability of tools' quality and levels of evidence. They both found it easy to use. They both thought the criteria used for grading were logical, clear, and well structured. They did not wish to add, remove, or change any of the criteria. However, they asked for adding some definitions and clarifications to the criteria, which was included in the update. 4. Discussion and Conclusion we present the validation of the GRASP framework through the feedback of a wide international group of experts, where the GRASP framework concept, evaluation criteria, and the detailed report have been updated based on their feedback. The reliability testing showed that the GRASP framework can be used reliably and consistently by independent users to grade predictive tools.
Brief Summary
Predictive Performance
The internal validation of the predictive performance of a tool is essential to make sure the tool is doing the prediction task as designed [43, 44] . 
Usability and Potential Effect
In addition to the predictive performance, clinicians are usually interested to learn about the potential effects of the tools on improving patient outcomes, saving time, costs and resources, or supporting patient safety [2, 51] . They need to know more about the expected impact of using the tool on different healthcare aspects, processes or outcomes, assuming the tool has been successfully implemented in the clinical practice [52, 53] . If a CDS tool has less potential to improve healthcare processes or clinical outcomes it will not be easily adopted or successfully implemented in the clinical practice [54] . Some clinicians might also be interested to learn about the usability of predictive tools; whether these tools can be used by the specified users to achieve specified and quantifiable objectives in the specified context of use [55, 56] .
CDS tools with poor usability will eventually fail, even if they provide the best performance or potential effect on healthcare [7, 57] . Usability includes several measurable criteria, based on the perspectives of the stakeholders, such the mental effort needed, the user attitude, interaction, easiness of use, and acceptability of systems [58, 59] . Usability can also be evaluated through measuring the effectiveness of task management with accuracy and completeness, the efficiency of utilising resources, and the users' satisfaction, comfort with, and positive attitudes towards, the use of the tools [60, 61], in addition to learnability, memorability and freedom of errors [62, 63].
Post-Implementation Impact
Clinicians are interested to learn about the post-implementation impact of CDS 
Direction of Evidence and Conflicting Conclusions
It is not uncommon to encounter conflicting conclusions when a predictive tool is validated or implemented and evaluated in different patient subpopulations or for different prediction tasks or outcomes [74, 75] . The cut-off value that determines what a good predictive performance is, for example, depends not only on the clinical condition under consideration but largely on the requirements, conditions, and consequences of the decisions made accordingly [76] . One of the main challenges here is dealing with the huge variability in the quality, types, and conditions of studies published in the literature. This variability makes it impossible to synthesise different measures of predictive performance, usability, potential effect or post-implementation impact into simple quantitative values, like in meta-analysis or systematic reviews [77, 78] .
The GRASP Framework Overall
The grades assigned to predictive tools, using the GRASP framework, provide relevant evidence-based information to guide the selection of predictive tools for clinical decision support. However, the framework is not meant to be precisely
prescriptive. An A1 tool is not always and absolutely better than an A2 tool. A clinician may prefer an A2 tool showing improved patient safety in two observational studies rather than an A1 tool showing reduced healthcare costs in three experimental studies.
It all depends on the objectives and priorities the users are trying to achieve, through implementing and using predictive tools in their clinical practice. More than one predictive tool could be endorsed, in clinical practice guidelines, each supported by its requirements and conditions of use and recommended for its most prominent outcome of predictive performance, potential effect, or post-implementation impact on healthcare and clinical outcomes. The GRASP framework remains a high-level approach to provide clinicians with an evidence-based and comprehensive, yet simple and feasible, method to evaluate and select predictive tools. However, when clinicians need further information, the framework detailed report provides them with the required details to support their decision making.
Challenges, Limitations, and Future Work
It might be easy to analyse the feedback of experts using closed-ended questions. However, analysing the feedback of experts using open-ended questions is rather difficult [79] . Qualitative content and thematic analysis of free text feedback is challenging, since the extraction of significance becomes more difficult with diverse opinions, different experiences, and variable perspectives [80] . It is advised by many healthcare researchers to use Delphi techniques to reach to consensus among experts, through successive rounds of feedback, when developing clinical guidelines or selecting evaluation criteria and indicators [81] [82] [83] . However, using the Delphi techniques was not feasible in our study.
Even though we contacted a large number of 882 experts, in the area of developing, implementing and evaluating predictive tools and CDS systems, we got a very low response rate of 9.2%, and received only 81 valid responses. This low response rate could have been improved if participants were motivated by some incentives, more than just acknowledging their participation in the study, or if more support was provided through the organisations these participants belong to, which needs much more resources to synchronise these efforts. For the sake of keeping the survey feasible for most busy experts, the number of the closed ended as well as the open-ended questions were kept limited and the required time to complete the whole survey was kept in the range of 20 minutes. However, some of the participants could have been willing to provide more detailed feedback, through interviews for example, which was out of the scope of this study and was not initially possible to conduct with all the invited experts, otherwise we would have received a much lower response rate.
To evaluate the impact of the GRASP framework on clinicians' decisions and examine the application of the framework to grade predictive tools, the authors are currently working on two more studies. The first study should validate and evaluate the impact of using the framework on improving the decisions made by end user clinicians and healthcare professionals, regarding selecting predictive tools for the clinical tasks.
Through an online survey of a wide international group of clinicians and healthcare professionals, the study should compare the performance and outcomes of making decisions with and without using the framework. The second study aims to apply the framework to a large consistent group of predictive tools, used for the same clinical prediction task. This study should show how the framework provides clinicians with an evidence-based method to compare, evaluate, and select predictive tools, through grading and reporting tools based on the critical appraisal of their published evidence.
To enable end user clinicians and clinical practice guideline developers to access detailed information, reported evidence and assigned grades of predictive tools, it is essential to discuss implementing the GRASP framework into an online platform.
However, maintaining such grading system up to date is a challenging task, as this requires the continuous updating of the predictive tools grading and assessments, when new evidence becomes published and available. It is important to discuss using automated or semi-automated methods for searching and processing new information to keep the GRASP framework updated. Finally, we recommend that the GRASP framework be utilised by working groups of professional organisations to grade predictive tools, in order to provide consistent results and increase reliability and credibility for end users. These professional organisations should also support disseminating such evidence-based information on predictive tools, in a similar way of announcing and disseminating new updates of clinical practice guidelines. 
Internal validation C3
Tested for internally validity (reported calibration & discrimination; sensitivity, specificity, positive and negative predictive values & other performance measures).
External validation C2
Tested for external validity, using one external dataset.
External validation multiple times C1 Tested multiple times for external validity, using more than one external dataset.
Phase B:
During implementation
Is it practicable?
Potential effect B2 Reported estimated potential effect on clinical effectiveness, patient safety or healthcare efficiency.
Usability
B1
Reported usability testing (effectiveness, efficiency, satisfaction, learnability, memorability, and minimizing errors).
Phase A:
Is it desirable?
Evaluation of post implementation impact on Clinical Effectiveness, Patient Safety or Healthcare Efficiency
A3
Based on subjective studies; e.g. the opinion of a respected authority, clinical experience, a descriptive study, or a report of an expert committee or panel.
A2
Based on observational studies; e.g. a well-designed cohort or case-control study.
A1
Based on experimental studies; properly designed, widely applied randomised/nonrandomised controlled trial.
Final Grade
Grade ABC,123 A1 A2 A3 B1 B2 C1 C2 C3
Direction of Evidence
Positive Evidence Mixed Evidence Supporting Positive Conclusion
Negative Evidence Mixed Evidence Supporting Negative Conclusion
Justification Explains how the final grade is assigned based on evidence; which conclusions were taken into consideration, as positive evidence, and which were considered negative.
References
Details of studies supporting justification: phase of evaluation, level of evidence, direction of evidence, study type, study settings, methodology, results, findings and conclusions (highlighted according to colour code).
These two sections are included in the full GRASP report on each tool. Insufficient internal validation C0 Not tested for internal validity, insufficiently internally validated, or internal validation was insufficiently reported.
Internal validation C3
External validation C2
Phase B:
Planning for implementation
Is it practicable?
Usability
B3
Reported usability testing (tool effectiveness, efficiency, satisfaction, learnability, memorability, and minimizing errors).
Potential effect B2
Reported estimated potential effect on clinical effectiveness, patient safety or healthcare efficiency.
Potential effect & Usability B1 Both potential effect and usability are reported.
A3
A2
A1
One-word description of the most prominent prediction, potential effect or impact on healthcare processes or outcomes. E.g. "Grade A2 -Efficiency" (the tool improves efficiency by saving money, resources or time, proved through observational post-implementation impact studies).
Direction of Evidence
Negative Evidence Mixed Evidence Supporting Negative Conclusion
Evidence Summary
Details of studies; using the Evidence Summary, to support the justification, where comparative predictive performance and effectiveness studies are highlighted.
Findings Codes
Positive Findings / Negative Findings / Important Findings Dedicated support of research networks, programs or groups.
The Evidence Summary
Authors 2
Number of researchers.
Journal 2
Journal name and impact factor.
Direction of Evidence
Positive / Equivocal / Negative (Based on study findings and conclusions).
Matching of Evidence
Considering fields 1 (Matching/Non-Matching to the tool's original specifications)
Quality of Evidence
Considering fields 2 (High Quality/Low Quality of the study)
Strength of Evidence
Based on Evidence Matching and Quality: Strong Evidence / Medium Evidence / Weak Evidence Label Effectiveness / Efficiency / Safety / Workflow / Processes (one or more).
Notes
Special important study information. 
Experts' Country Distributions
The Mixed Evidence Protocol
The mixed evidence protocol is based on four steps. Firstly, it considers the degree of matching between the evaluation study conditions and the original tool specifications, in terms of the predictive task, outcome, intended use and users, clinical specialty, healthcare settings, target population, and age group. Secondly, it considers the quality of the study, in terms of sample size, data collection, study methods, and credibility of institute or authors. Based on these two criteria, the studies in the mixed evidence on the tool are classified into 1) Class A: matching evidence of high quality, 2) Class B: matching evidence of low quality or non-matching evidence of high quality, and 3) Class C: non-matching evidence of low quality. Thirdly, it considers the evidence conclusion on the reported evaluation criteria; the predictive performance, potential effect, usability, and post-implementation impact. In the fourth step, studies evaluating predictive tools in closely matching conditions to the tool specifications and providing high quality evidence, Class A, are considered first; taking into account their conclusions on the evaluation criteria in deciding the overall direction of evidence. On the other hand, studies evaluating predictive tools in different conditions to the tool specifications and providing low quality evidence, Class C, are considered last. The conclusion of one study in Class A is considered a stronger evidence than the conflicting conclusions of any number of studies in Class B or C, and the overall direction of the evidence is decided towards the conclusion of the study of Class A.
When multiple studies of the same class; for example, Class A, report conflicting conclusions, then we compare the number of studies reporting positive conclusions to those reporting negative conclusions and the overall direction of the evidence is decided towards the conclusion of the larger group. If the two groups are of the same size, then we check if there are more studies in other classes, if not then we examine the reported evaluation criteria and their values in the two groups of studies. Step 1
Strong Evidence
Step 
